Tenax Therapeutics (TENX) Net Income towards Common Stockholders (2016)
Historic Net Income towards Common Stockholders for Tenax Therapeutics (TENX) over the last 6 years, with Q4 2016 value amounting to $33.9 million.
- Tenax Therapeutics' Net Income towards Common Stockholders rose 37972.22% to $33.9 million in Q4 2016 from the same period last year, while for Sep 2017 it was $33.9 million, marking a year-over-year increase of 25913.32%. This contributed to the annual value of -$17.6 million for FY2024, which is 12643.43% down from last year.
- Per Tenax Therapeutics' latest filing, its Net Income towards Common Stockholders stood at $33.9 million for Q4 2016, which was up 37972.22% from -$4.5 million recorded in Q3 2016.
- In the past 5 years, Tenax Therapeutics' Net Income towards Common Stockholders registered a high of $118.0 million during Q2 2013, and its lowest value of -$12.1 million during Q4 2015.
- In the last 4 years, Tenax Therapeutics' Net Income towards Common Stockholders had a median value of -$3.0 million in 2012 and averaged $22.4 million.
- Within the past 5 years, the most significant YoY rise in Tenax Therapeutics' Net Income towards Common Stockholders was 371057.81% (2012), while the steepest drop was 35790.41% (2012).
- Over the past 4 years, Tenax Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$1.6 million in 2012, then surged by 7711.24% to $118.0 million in 2013, then crashed by 110.26% to -$12.1 million in 2015, then soared by 379.72% to $33.9 million in 2016.
- Its Net Income towards Common Stockholders was $33.9 million in Q4 2016, compared to -$4.5 million in Q3 2016 and -$4.7 million in Q2 2016.